Where the catalyst calendar stands
Three dated events frame the quarter. Summit Therapeutics' Biologics License Application for ivonescimab, based on the HARMONi trial, carries an FDA action date of November 14, 2026.1 Moderna and Merck plan to present detailed intismeran results at ESMO on October 24 and to engage with regulators about potential filings.2 The third has already happened. On October 8, the EXCALIBER-RRMM Phase 3 reported topline results. The ZDd arm showed median progression-free survival of 42 months against 20 months for DVd (hazard ratio 0.49, p<0.000001), a 51% reduction in the risk of progression or death, with median follow-up of 23 months.3
Those are the only hard dates in our material. We do not have share-price data for any of these companies, so we cannot say how much of this is already reflected in prices. Anyone claiming to know from this material alone is guessing.
The combination bet: ivonescimab plus Datroway
On October 2, Summit announced a clinical trial collaboration with Daiichi Sankyo and AstraZeneca to test ivonescimab with Datroway across multiple solid tumor settings, intending to include breast and lung cancer.4 The read-through for traders is that a bispecific antibody and an antibody-drug conjugate (ADC) are being lined up as a pair, not just competitors. The collaboration is a trial agreement, not efficacy data. The November 14 FDA date applies to ivonescimab on its own HARMONi-based filing,1 so the combination story is further out than the approval question. Keep the two separate.
Merck: a vaccine partner with a balance sheet that moves
Merck is the partner in the intismeran vaccine program, so its SEC-filed numbers are the best verified data we have on how much room it has to fund oncology. Our dossier does not give Merck's weight in any index fund, so we will not guess whether you already own it through one.
Cash is volatile, and that is the main point. Merck reported $18.169 billion in cash at the end of Q3 2025,5 $14.565 billion at year-end 2025,5 $5.327 billion at Q1 2026,5 and $6.849 billion at Q2 2026.5 By our arithmetic, the Q3 2025 figure is about 2.7 times the latest one. The filings in our dossier do not say why cash fell, so we do not attribute it to any deal or payout. Swings of this size are not new. Q2 cash was $5.66 billion in 2023, $11.304 billion in 2024 and $8.007 billion in 2025.5 A single quarter's cash balance is a weak signal for this company.
Spending on plant and equipment (capex) has been steadier: $3.863 billion in FY2023, $3.372 billion in FY2024 and $4.112 billion in FY2025.6 Q1 2026 capex was $991 million, against $1.328 billion in Q1 2025.6 Spending is not accelerating in the latest quarter we can see.
Cost of revenue, the direct cost of producing what the company sells, rose faster. It was $4.395 billion in Q2 2026 against $3.557 billion in Q2 2025,7 and $4.195 billion in Q1 2026 against $3.419 billion in Q1 2025.7 By our calculation that is roughly 23% to 24% higher in both quarters. The dossier has no revenue figures, so we cannot say whether margins shrank. It is a cost line to watch, not a conclusion.
Who is actually earning: Novocure and the commercial side
Novocure (NASDAQ: NVCR) reported Q2 2026 net revenues of $184 million, up 16% year over year, driven by 18% growth in global active patients.8 It reported more than 280 active patients on Optune Pax as of June 30, 2026, and a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch.8 CEO-level commentary was upbeat. Frank Leonard said: "This was our strongest quarter to date, with record net revenues and active patients on therapy."8 That is the company describing itself. The revenue and patient figures are the checkable part.
Kiniksa is described in our narrative as reporting a strong quarter, but our dossier contains no Kiniksa figures, so we leave it at that.
Gilead (NASDAQ: GILD) had a regulatory step on July 24. The EU's drug committee (CHMP) recommended Trodelvy plus Keytruda in first-line PD-(L)1-positive metastatic triple-negative breast cancer.9 A recommendation is not an approval. As Evandro de Azambuja put it, if authorized it would build on the recent approval of Trodelvy monotherapy and help establish a Trodelvy-based approach in first line across PD-L1 status.9 Separately, Telix dosed the first patient in the Phase 3 LUTEON trial of TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma, the first radiopharmaceutical therapy to enter Phase 3 in that cancer.10 That is an early-stage milestone, not a revenue event.
The small-cap squeeze: ADC Therapeutics
Capital is not reaching everyone. ADC Therapeutics cut jobs, projecting "$10 million in annualised cost savings."11 The company says it "maintains a cash runway into 2028, supporting ongoing regulatory and clinical plans for ZYNLONTA combinations."11 Both statements come from the company. For holders, the practical meaning is that management is choosing to stretch its money until 2028 and is not raising fresh cash now. A runway claim is only as good as the spending that follows it.
AstraZeneca's AI pitch: a promise, not a result
AstraZeneca's Puja Sapra says proprietary data is the differentiator: "Data is our differentiator."12 She describes a "lab of the future" in which "this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data."12 She also names the hard part: "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body."12 And she says human oversight stays central: "With more autonomous systems, human oversight remains at the heart of this approach."12
Nothing in this material shows an AI-designed drug that has reached patients, or a measured cut in discovery time. The article describes potential ("have the potential to help accelerate early drug development timelines significantly").12 For a trader, this is a long-dated narrative and not a near-term catalyst.
How much to trust the sources
We measure how often claims from each source have held up when checked. The wire-service items for Novocure and Gilead come from a source where 56% of 4,956 checked claims held up.8,9 The Telix item comes from a source where 31% of 2,928 checked claims held up.10 The weekly biotech roundup carrying the ADC Therapeutics statements scored 45% of 520.11 The MIT Technology Review piece quoting Sapra scored 0% of 11 checked claims.12 That sample is small, so we read it as a caution and not a verdict. The Merck SEC-filing figures are the most solid numbers here. The company quotes are statements of intent and should be read that way. The event-calendar items come from our event tracking and are not tied to a single published document.
What to watch
- Oct. 24: the detailed intismeran data at ESMO, and what Merck and Moderna say about filings.2
- Nov. 14: the FDA decision date for ivonescimab.1
- Merck's next filing: whether cash rebuilds from $6.849 billion and whether cost of revenue keeps running about a quarter above last year.5,7
- Gilead: whether the CHMP recommendation becomes a formal authorization.9
- ADC Therapeutics: whether the 2028 runway holds as it pursues ZYNLONTA combinations.11
